Loxo Oncology, Inc. Company Profile

04:44 EDT 20th September 2018 | BioPortfolio

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery.

News Articles [509 Associated News Articles listed on BioPortfolio]

License Agreement: Array Biopharma, $ARRY (Loxo Oncology, $LOXO)

July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain ...

Illumina and Loxo Oncology Join Forces to Develop Pan-Cancer Companion Diagnostics

Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a compan...

Loxo Oncology Stocks Jump After Positive Data Released at ASCO Preview

Loxo Oncology shares climbed 19 percent after data for its cancer drug LOXO-292 was released.

Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

STAMFORD, Conn., April 04, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genet...

Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

– LOXO-292 Phase 1 Clinical Trial Abstract Selected for “Best of ASCO” – – Company to Host Conference Call and Webcast on Saturday, June 2nd at 4:00 p.m. CT – STAMFORD, Conn., May 16,...

Illumina announces strategic partnership with Loxo Oncology

Illumina and Loxo Oncology will collaborate on the development and commercialization of a next-generation sequencing-based co -More- 

Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting

– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumo...

Illumina, Loxo Oncology partner to develop multi-gene panel for tumor profiling

Illumina and Loxo Oncology have partnered on the development of next-generation sequencing-based pan-cancer companion diagnostics.

PubMed Articles [1210 Associated PubMed Articles listed on BioPortfolio]

LOXO-292 Reins In RET-Driven Tumors.

LOXO-292, a selective and potent RET inhibitor, led to tumor shrinkage in fusion-positive and -mutant cancers alike, according to phase I data reported at the 2018 American Society of Clinical Oncolo...

Nonspecialty Nurse Education: Evaluation of the Oncology Intensives Initiative, an Oncology Curriculum to Improve Patient Care.

A community hospital combined its medical and surgical patients with cancer on one unit, which resulted in nurses not trained in oncology caring for this patient population.

Burnout and Resiliency in Canadian Oncology Residents: a Nationwide Resident and Program Director Survey.

To measure burnout rates and resiliency scores in Canadian Oncology residents and to advance the knowledge regarding resiliency and wellness training in Canadian Oncology residency programs.

Development of a Virtual Radiation Oncology Clinic for training and simulation of errors in the radiation oncology workflow.

The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.

To describe the US hematology and medical oncology practice landscape and to report findings of the sixth annual ASCO Oncology Practice Census survey.

Clinical Trials [537 Associated Clinical Trials listed on BioPortfolio]

Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

LOXO-195 expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing LOXO-195 clinical trial or have other considerations that p...

Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors

This is a multicenter, open-label, Phase 1 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 will be administered orally (PO) twice daily (BID), with the do...

Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion

Larotrectinib (LOXO-101) expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing larotrectinib (LOXO-101) clinical trial or ...

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers

This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients with NTRK fusion cancers treated with prio...

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors

Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

Companies [733 Associated Companies listed on BioPortfolio]

Loxo Oncology, Inc.

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer...

Takeda Oncology

Takeda Oncology, headquartered in Cambridge, MA, delivers novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion ...


OncLive is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary O...

Cold Spring Publishing, LLC

Cold Spring Publishing, LLC, (CSP) is a medical publishing company whose principals have more than 50 years of combined publishing experience, with a specific focus in oncology. CSP publishes JNCCN --...

Michiana Hematology-Oncology,P.C.

Michiana Hematology-Oncology,P.C. is the premier provider of medical oncology, gynecologic oncology and adult hematology services in North-Central Indiana and Southwestern Lower Michigan.Michiana Hema...

More Information about "Loxo Oncology, Inc." on BioPortfolio

We have published hundreds of Loxo Oncology, Inc. news stories on BioPortfolio along with dozens of Loxo Oncology, Inc. Clinical Trials and PubMed Articles about Loxo Oncology, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Loxo Oncology, Inc. Companies in our database. You can also find out about relevant Loxo Oncology, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Corporate Database Quicklinks

Searches Linking to this Company Record